HSP90AB1 and type 2 diabetes mellitus: Genetic manipulation or pharmacological methods have demonstrated that blocking HSP90β can greatly improve obesity-related fatty liver disease, type 2 diabetes, and atherosclerosis by suppressing SREBP function.